RSV Overview - The Tiny Terror
- Virus: Enveloped, negative-sense, single-stranded RNA paramyxovirus.
- Pathogenesis: Infects respiratory epithelium, causing cell fusion and formation of large multinucleated cells (syncytia). This leads to inflammation, mucus production, and airway obstruction.
- Clinical: Leading cause of bronchiolitis and pneumonia in infants <1 year old. Presents with fever, cough, wheezing, and respiratory distress.
- Seasonality: Peaks in winter months.
⭐ High-Yield: RSV is the most common cause of lower respiratory tract illness (LRTI) in children worldwide, hospitalizing millions annually.
Monoclonal Antibodies - Protein Bodyguards
*Passive immunity via lab-engineered antibodies to prevent severe RSV disease in high-risk infants. These do not treat active infection.
-
Palivizumab
- Mechanism: Humanized IgG1 monoclonal antibody that targets a specific epitope (site A) on the RSV fusion (F) protein. This blocks viral entry into host cells.
- Indication: Prophylaxis for infants at high risk:
- Preterm infants (< 29 weeks gestation)
- Chronic Lung Disease of Prematurity (CLDP)
- Hemodynamically significant congenital heart disease.
- Administration: Given as a monthly intramuscular (IM) injection throughout the RSV season (typically November to March).
-
Nirsevimab
- Mechanism: Next-generation monoclonal antibody, also targets the F protein.
- Advantage: Longer half-life due to a modified Fc region, requiring only a single IM dose for the entire RSV season.
⭐ High-Yield: Palivizumab is a prophylactic antibody, not a vaccine. It provides passive immunity but does not induce an active, long-term memory immune response from the host.

Ribavirin - The Risky Rescue
- Mechanism: Guanosine analog; inhibits viral RNA polymerase & IMP dehydrogenase, depleting GTP and causing lethal viral mutations.
- Use: Reserved for severe RSV infections in immunocompromised adults (e.g., transplant patients). Aerosolized administration.
- Toxicity:
- ⚠️ Extreme Teratogen: Contraindicated in pregnancy (patient or partner).
- Dose-dependent hemolytic anemia.
- Bronchospasm (inhaled route).
⭐ Ribavirin's most tested adverse effect is its teratogenicity, requiring strict contraception for both male and female patients during and for 6 months after therapy.
📌 Mnemonic: RIBA
- RNA polymerase inhibitor
- IMP Dehydrogenase inhibitor
- Bad for Baby
- Anemia

High‑Yield Points - ⚡ Biggest Takeaways
- Palivizumab is a monoclonal antibody used for prophylaxis in high-risk infants; it is not a treatment for active infection.
- It targets the RSV F protein, preventing viral fusion and entry.
- Ribavirin is reserved for severe RSV infections, primarily in immunocompromised patients.
- A major adverse effect of Ribavirin is teratogenicity, making it contraindicated in pregnancy.
- The mechanism of Ribavirin involves inhibiting inosine monophosphate dehydrogenase, depleting GTP.
- Supportive care remains the primary management for most RSV cases.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app